Universa Medicina
Vol 29, No 3 (2010)

Warfarin: do we need genotype-based dose prediction?

Yenny, Yenny (Unknown)

Article Info

Publish Date
25 Feb 2016

Abstract

For the treatment and prevention of thrombo-embolic disease, the most frequently used anticoagulant drug worldwide is warfarin, an oral coumarin derivative, with more than 30 million prescriptions written for this drug in the United States in 2004.(1) The drug has a narrow therapeutic index and its metabolism varies by as much as a factor of 10 among individual patients, making warfarin therapy difficult to manage. Hemorrhagic complication rates of warfarin are estimated to be 5-7.9% for major (life threatening) hemorrhage and 14-36% for minor hemorrhage (e.g. nosebleeds, microscopic hematuria).(2) This condition makes it difficult to establish the appropriate dose of warfarin.

Copyrights © 2010




Citation Download
RIS
EndNote, Reference Manager, ProCite
BibTex
Latex, Jabref
Original Source
Download Original
Google Scholar
Check in Google Scholar
Journal Info
Universa Medicina
Website

Abbrev

medicina

Publisher

Universitas Trisakti

Subject

Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Description

Universa Medicina (univ.med) is a four-monthly medical journal that publishes new research findings on a wide variety of topics of importance to biomedical science and clinical practice. Universa Medicina Online contains both the current issue and an online archive that can be accessed through ...